Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1  identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...